JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412764.2", 
          "name": [
            "Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Hiroyuki", 
        "id": "sg:person.0635431612.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635431612.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Kawasaki Rinko General Hospital, Kawasaki, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan", 
            "Department of Internal Medicine, Kawasaki Rinko General Hospital, Kawasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watanabe", 
        "givenName": "Yoshiyuki", 
        "id": "sg:person.01016570574.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016570574.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412764.2", 
          "name": [
            "Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Itoh", 
        "givenName": "Fumio", 
        "id": "sg:person.0623252706.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623252706.86"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2019-05-31", 
    "datePublishedReg": "2019-05-31", 
    "description": "Cell-free DNA (cfDNA) found in the plasma or serum is derived from multiple sources, including tumor cells. The fraction of cfDNA derived from tumor cells is termed circulating tumor DNA (ctDNA). Despite the low levels of ctDNA in normal cfDNA, advances in digital polymerase chain reaction (PCR) and next-generation sequencing (NGS) technologies have led to significant improvements in the sensitivity and specificity of variant detection. As a result, the literature regarding ctDNA assays has been rapidly increasing. The genomic profiles of ctDNA have been shown to closely match those of the corresponding tumors, which has important implications for both molecular pathology and clinical oncology. Noninvasive diagnostic techniques using ctDNA have the potential to innovate new prognostic factors and direct treatment intervention. Analyses of ctDNA, commonly referred to as \u201cliquid biopsies,\u201d can be used for treatment selection, treatment outcome monitoring, residual disease detection, cancer screening in asymptomatic individuals, and tumor dynamics monitoring. In this chapter, we summarize how different ctDNA assays can be used to guide patient care and should be integrated into the clinical practice.", 
    "editor": [
      {
        "familyName": "Shimada", 
        "givenName": "Hideaki", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-981-13-7295-7_2", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-981-13-7294-0", 
        "978-981-13-7295-7"
      ], 
      "name": "Biomarkers in Cancer Therapy", 
      "type": "Book"
    }, 
    "keywords": [
      "cell-free DNA", 
      "polymerase chain reaction", 
      "ctDNA assays", 
      "normal cell-free DNA", 
      "tumor cells", 
      "treatment outcome monitoring", 
      "new prognostic factors", 
      "residual disease detection", 
      "noninvasive diagnostic techniques", 
      "prognostic factors", 
      "cancer screening", 
      "asymptomatic individuals", 
      "treatment selection", 
      "Clinical Oncology", 
      "clinical practice", 
      "treatment interventions", 
      "patient care", 
      "tumor DNA", 
      "outcome monitoring", 
      "digital polymerase chain reaction", 
      "liquid biopsy", 
      "molecular pathology", 
      "chain reaction", 
      "genomic profiles", 
      "diagnostic techniques", 
      "significant improvement", 
      "low levels", 
      "assays", 
      "cells", 
      "biopsy", 
      "disease detection", 
      "tumors", 
      "pathology", 
      "oncology", 
      "serum", 
      "care", 
      "intervention", 
      "screening", 
      "important implications", 
      "next-generation sequencing technologies", 
      "variant detection", 
      "DNA", 
      "specificity", 
      "monitoring", 
      "individuals", 
      "levels", 
      "factors", 
      "plasma", 
      "dynamic monitoring", 
      "detection", 
      "sensitivity", 
      "improvement", 
      "profile", 
      "advances", 
      "practice", 
      "sequencing technologies", 
      "literature", 
      "fraction", 
      "multiple sources", 
      "potential", 
      "analysis", 
      "implications", 
      "results", 
      "reaction", 
      "selection", 
      "technique", 
      "chapter", 
      "source", 
      "technology"
    ], 
    "name": "Cell-Free DNA", 
    "pagination": "11-24", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1116020184"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-981-13-7295-7_2"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-981-13-7295-7_2", 
      "https://app.dimensions.ai/details/publication/pub.1116020184"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-08-04T17:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/chapter/chapter_182.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-981-13-7295-7_2"
  }
]

Download the RDF metadata as:  json-ld nt turtle xml License info

This table displays all metadata directly associated to this object as RDF triples.

146 TRIPLES      22 PREDICATES      92 URIs      85 LITERALS      7 BLANK NODES